Collegium Pharmaceutical, Inc. (COLL)
| Previous Close | 33.20 |
| Open | 33.03 |
| Bid | 23.98 x 200 |
| Ask | 42.30 x 200 |
| Day's Range | 32.76 - 33.65 |
| 52 Week Range | 20.83 - 40.95 |
| Volume | |
| Avg. Volume | 450,130 |
| Market Cap | 1.1B |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | 13.39 |
| EPS (TTM) | 2.51 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
GuruFocus.comInsider Sale: EVP & CFO Colleen Tupper Sells Shares of Collegium Pharmaceutical Inc (COLL)
On May 28, 2024, Colleen Tupper, Executive Vice President and Chief Financial Officer of Collegium Pharmaceutical Inc (NASDAQ:COLL), executed a sale of 19,710 shares of the company.
GlobeNewswireCollegium to Participate in Jefferies Global Healthcare Conference
STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, June 5, 2024, at 9:30 a.m
- GlobeNewswire
Collegium Announces $35 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized b
